Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial

Key Points

This trial aims to evaluate the efficacy of Lactobacillus johnsonii LA1 in preventing postoperative recurrence of Crohn's disease.
Randomized double-blind placebo-controlled trial
Involved administration of Lactobacillus johnsonii LA1 (4 x 10(9) cfu/day)
Participants monitored for endoscopic recurrence of Crohn's disease.
Lactobacillus johnsonii LA1 did not demonstrate a significant effect on preventing endoscopic recurrence of Crohn's disease.
No sufficient evidence found for effectiveness compared to placebo.

Answers are grounded in this paper and cite their sources.

Randomized trial assesses Lactobacillus johnsonii LA1 for Crohn's disease recurrence, suggesting limited effectiveness.

L johnsonii LA1 (4 x 10(9) cfu/day) did not have a sufficient effect, if any, to prevent endoscopic recurrence of Crohn's disease.

No takes yet. Share an insight, caveat, or question.

Marteau et al. (2005) studied this question.

View Full Paper

Ask AI

Bookmark

Share